At a medical conference I asked a Chairman of Medicine of a prestigious university how he would treat a man who had a massive heart attack with a cholesterol of only 140, LDL of 50, normal coronary arteries, and no other risk factors. He said ‘That’s a no brainer – give him a high dose statin.’ I then said, “That man’s cholesterol, LDL and coronary arteries are excellent. It’s probably only inflammation or a clot, so one could use vitamins and other nutrients instead.” He abruptly and arrogantly said ‘No, give him a statin’ and he turned away. This is what Big Pharma does. They pay so-called “thought leaders” to influence other doctors to prescribe their drugs. And these “thought leaders” must not deviate from the written words given to them by Big Pharma.
Amgen, the maker of evolocumab (Repatha) funded the research, paid EVERY author on the paper, led by Harvard researchers, and the findings were published in the prestigious New England Journal of Medicine May 4, 2017. If you take the drug, evolocumab (Repatha), your LDL will go down but you won’t live any longer. IT’S ALL ABOUT INFLAMMATION AND OXIDATION.
INFLAMMATION AND OXIDATION DECREASE ATHLETIC PERFORMANCE AND INCREASE THE RISK FOR CANCER, CARDIOVASCULAR DISEASE, DIABETES, DEMENTIA, AND MANY OTHER CHRONIC DISEASES AS WELL AS SHORTENED LIFESPANS